Who we are
WHAT WE DO
Our work is founded on the teachings of Deming, Juran, Shingo, Ohno, and many other great exponents from exemplar sectors such as automotives and semi-conductor.
Just as these sectors have placed their ‘systems of production’ at the heart of their business, with transformational effect, so can Biopharmaceuticals leverage that learning in the previously untapped world of drug production.
WHO WE WORK WITH
Clients range from large pharmaceutical companies to emerging biotech, and also include investors, lawyers, other consultancies, facility design & build specialists and third party logistics providers (3PLs).
Assignments span early stage clinical trial supply chains up to complex multi-product supply networks covering global territories.
Current Industry Insights & Issues
The penicillin story is well known. For those that need reminding, the mother of all antibiotics was ... Read more!
"Too little is known about a molecule’s potential to become a drug when it enters development. Only one in 250 ... Read more!
In previous posts, I promised to outline a new model for drug development, and now is the time to lay out the ... Read more!
This may seem like a strange assertion to some, but consider the facts. Since the early 1980’s, Big Pharma ... Read more!
Very interesting and refreshing approach to drug development. Using supply chain management as a method [Hedley] reviews current industry practice from drug inception to commercialization, spelling out clear limitations and suggesting a number of daring ideas that could dramatically change how new therapeutics are developedJesús Zurdo, Head of Innovation, Biopharma Development, Lonza Biologics
Hedley Rees' book is a timely antidote to the faddish advice and writing about outsourcing and lean supply chain management that has bedevilled good practice in the industry, and in supply chain management thinking in generalProfessor Andrew Cox, Chairman, Advisory Board, International Institute for Advanced Purchasing & Supply (IIAPS), former Director of the Centre for Business Strategy and Procurement at Birmingham University Business School, the first ever MBA in Strategic Procurement Management.
37 years in the industry but I never saw the production side in this light; I have learned a lot. Rees has a keen eye for what could go wrong in the drug maker's supply chain.James O'Reilly, Professor in FDA Law at the University of Cincinnati and Chair of the FDA Committee of the American Bar Association